A study of a GLP-1 and GIP medicine, tirzepatide, in people with idiopathic intracranial hypertension (IIH).
Recruiting now. Registry record last updated August 28, 2026.
- Who can join
- Adults 18 to 60, have idiopathic intracranial hypertension (IIH), BMI 30+.
- What you take
- Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 2 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Idiopathic Intracranial Hypertension (IIH).
Full scientific study title: Tirzepatide in Idiopathic Intracranial Hypertension Trial.
Who can join
Adults 18 to 60, have idiopathic intracranial hypertension (IIH), BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Signs and symptoms of increased intracranial pressure:
- headaches, tinnitus, visual obscurations, papilledema;
- absence of localizing findings on neurological examination (except for VI nerve palsy);
- no secondary causes identified on imaging, e.g., hydrocephalus, space- occupying lesion;
- elevated lumbar puncture (LP) opening pressure (OP) ≥25 cm H2O in lateral decubitus position with legs extended (\>= (≥ 20 cm H2O if one of the following is present: pulse synchronous tinnitus, abducens palsy, Frisen grade II papilledema, transverse venous sinus stenosis, partially empty sella or enlarged optic nerve sheath on magnetic resonance imaging (MRI);
Key exclusion criteria
- Previous bariatric surgery
- Prior intervention for high ICP including optic nerve sheath fenestration (ONSF), venous stenting and/or shunting
- Taking another GLP-1 agonist, another drug that can interfere with the GLP-1 agonist, or any other anti-obesity medication
- History of pancreatitis, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), history of gallbladder disease, ulcerative colitis, Crohn's disease, or history of hypersensitivity reaction in response to the drug
- Pregnancy or planning a pregnancy in the next 12 months or currently breastfeeding
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
North Carolina1 site
- Duke University Medical CenterDurham, North Carolina
Timeline
Started enrolling: August 25, 2026. Expected completion: August 2028. Last updated on ClinicalTrials.gov: August 28, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
